Analysts forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will announce sales of $7.85 million for the current quarter, Zacks reports. Three analysts have provided estimates for Pieris Pharmaceuticals’ earnings. The highest sales estimate is $10.71 million and the lowest is $5.00 million. Pieris Pharmaceuticals reported sales of $4.15 million during the same quarter last year, which would suggest a positive year over year growth rate of 89.2%. The firm is expected to report its next earnings results before the market opens on Friday, May 10th.

On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.20 million for the current fiscal year, with estimates ranging from $20.40 million to $35.58 million. For the next fiscal year, analysts anticipate that the firm will report sales of $25.41 million, with estimates ranging from $13.33 million to $33.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.05). Pieris Pharmaceuticals had a negative net margin of 84.75% and a negative return on equity of 64.64%. The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $6.92 million.

PIRS has been the topic of several recent analyst reports. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $7.00 target price (up from $5.00) on shares of Pieris Pharmaceuticals in a research report on Friday, May 10th. Zacks Investment Research upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research report on Thursday, March 21st. ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Finally, Robert W. Baird initiated coverage on Pieris Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Several hedge funds have recently bought and sold shares of PIRS. SG Americas Securities LLC acquired a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at about $36,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Pieris Pharmaceuticals in the first quarter valued at about $36,000. Prudential Financial Inc. acquired a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at about $43,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Pieris Pharmaceuticals in the first quarter valued at about $57,000. Finally, Alambic Investment Management L.P. acquired a new stake in shares of Pieris Pharmaceuticals in the fourth quarter valued at about $59,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Shares of NASDAQ:PIRS traded down $0.16 on Tuesday, hitting $3.65. The company had a trading volume of 1,901 shares, compared to its average volume of 366,440. Pieris Pharmaceuticals has a 52-week low of $2.39 and a 52-week high of $6.55. The company has a market capitalization of $190.71 million, a P/E ratio of -7.18 and a beta of 1.78.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Further Reading: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.